@article = {{Busse1800948,作者威廉·w·会和人g . Brusselle斯蒂芬妮·科恩和彼得亚雷库纳安东尼Magnan和大卫·科恩和卡琳·鲍恩和特蕾莎修女Piechowiak和米莉~ M。小王和基因Colice},标题= {Tralokinumab没有证明口服corticosteroid-sparing效应严重哮喘},体积= {53}= {2},elocation-id = {1800948} = {2019}, doi ={10.1183/13993003.00948 -2018},出版商={欧洲呼吸学会},文摘={长期口服皮质类固醇(OCS)使用严重哮喘患者与重大的不良影响。188bet官网地址这40周,随机,双盲试验评估的OCS-sparing潜力tralokinumab严重,患者不受控制的哮喘需要商务治疗+吸入型皮质类固醇激素/长效β2-agonists维护。总体而言,140名患者被随机tralokinumab 300毫克或安慰剂每组(n = 70)皮下接种每2周。主要终点是百分比变化从基线平均40周后口服剂量,同时维持哮喘控制。二级终端包括比例的规定维护患者口服剂量的< = 5毫克,那些有> = 50 \ %减少处方剂量维护OCS和哮喘恶化率。安全也得到了评估。从基线下降40周,最后平均每日口服剂量tralokinumab和安慰剂之间没有明显不同(37.62和29.85 \ \ % %;p = 0.271)。没有任何二次端点处理间差异显著。总体而言,报告的不良事件和严重不良事件是相似的tralokinumab和安慰剂组。 Although a greater proportion of tralokinumab-treated patients reported upper respiratory tract infections (35.7\% versus 14.3\%), there were no reported cases of pneumonia.Overall, tralokinumab did not demonstrate an OCS-sparing effect in patients with severe asthma.Tralokinumab did not demonstrate significant OCS-sparing benefits versus placebo in severe asthma http://ow.ly/kzCt30mC43j}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/53/2/1800948}, eprint = {//www.qdcxjkg.com/content/53/2/1800948.full.pdf}, journal = {European Respiratory Journal} }